AstraZeneca Reports Results from the P-III (TOPAZ-1) Study of Imfinzi for Treating Advanced Biliary Tract Cancer
Shots:
- The P-III (TOPAZ-1) study investigates Imfinzi + CT (gemcitabine + cisplatin) vs CT + PBO as a 1L treatment of unresectable, locally advanced/metastatic biliary tract cancer patients (n=685) with intrahepatic & extrahepatic cholangiocarcinoma as well as gallbladder cancer
- The updated exploratory data of the study demonstrated a reduction in the death risk by 26%, mOS of 12.9mos. vs 11.3mos. at a median follow-up of 41.3mos. (>3yrs.) and OS rate of 14.6% vs 6.9% at 36mos.
- Additionally, the trial reached its 1EP of OS at a planned interim analysis depicting a reduction in the death risk by 20% in Oct 2021
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports Data from the P-III Study of Imfinzi as a Treatment of Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
